Robert Hazlett
Stock Analyst at BTIG
(1.16)
# 3,705
Out of 4,967 analysts
23
Total ratings
39.13%
Success rate
-7.93%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $6.31 | +280.35% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $60 | $29.09 | +106.29% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $0.47 | +2,904.29% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $1,200 → $1,000 | $7.41 | +13,395.28% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $123.47 | -20.63% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $9.22 | +550.76% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $4.52 | +1,293.81% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $8.27 | +250.67% | 4 | Feb 2, 2021 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $1.30 | +1,999,900.00% | 1 | Sep 11, 2020 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $26 → $6 | $3.11 | +92.93% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $14.29 | +25.96% | 2 | Aug 31, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $6.31
Upside: +280.35%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $60
Current: $29.09
Upside: +106.29%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $0.47
Upside: +2,904.29%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $1,200 → $1,000
Current: $7.41
Upside: +13,395.28%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $123.47
Upside: -20.63%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $9.22
Upside: +550.76%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $4.52
Upside: +1,293.81%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $8.27
Upside: +250.67%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $1.30
Upside: +1,999,900.00%
Akebia Therapeutics
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $3.11
Upside: +92.93%
Aug 31, 2017
Initiates: Buy
Price Target: $18
Current: $14.29
Upside: +25.96%